EUVIMEDEUVIMED entdecken
Crossref

Evaluation of cumulative absorbed dose in tumors of various sizes regarding 227Th-based targeted alpha therapy: an in-depth analysis

Sepideh Shafiei, Hassan Yousefnia

Annals of Nuclear Medicine · 2026

DOI: 10.1007/s12149-025-02100-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Nuclear Medicine, 2026. Verfasst von Sepideh Shafiei und 1 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Applications Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran. sshafiei@aeoi.org.ir. Hauptthemen laut MEDLINE: Alpha Particles, Thorium, Neoplasms, Radiation Dosage. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Producing several alpha-emitting isotopes in the decay chain of 227Th-based radiopharmaceuticals has increased the complexity of determining the optimal therapeutic dose. This research aims to assess the contribution of each thorium progeny to the cumulative dose in the tumor over time. This assessment will help determine the required injected activity and the appropriate characteristics of a 227Th-based radiopharmaceutical that can provide an adequate dose to induce sufficient cytotoxicity for effective treatment. METHODS: The cumulative dose in tumors of various sizes (with radii of 0.6, 1.2, and 1.8 cm) resulting from the decay of 227Th was calculated using MCNPX. The radial and temporal distribution of the absorbed dose within the tumor was studied, along with the contribution of each radioisotope to the cumulative dose over time throughout the tumor. Validation of the calculation was performed by determining the cumulative dose of 227Th-rituximab based on the experimental biodistribution, tumor size and mice weight reported in the literature. RESULTS: The cumulative dose within the tumor increases over time and is inversely proportional to the tumor's volume. The radial distribution of the cumulative dose within the tumor indicated that 227Th-based radiopharmaceuticals do not harm the healthy tissue surrounding the tumor. CONCLUSIONS: By taking into account the size of the tumor and the required therapeutic dose, the proposed calculation method can be employed to determine the necessary injected activity and characteristics of a radiopharmaceutical. This includes identifying a suitable retention time and tumor uptake to improve therapeutic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alpha ParticlesThoriumNeoplasmsRadiation DosageAbsorption, RadiationAnimalsMiceTissue DistributionRadiopharmaceuticalsHumansCell Line, TumorRadiotherapy Dosage

Stichwörter der Autor:innen

227Th-based radiopharmaceuticalsCumulative doseMonte Carlo simulationsRadial distribution of absorbed doseTargeted alpha therapyTime dependence of absorbed dose

Substanzen

ThoriumThorium-227Radiopharmaceuticals

Autor:innen und Institutionen

  • Radiation Applications Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran. sshafiei@aeoi.org.ir.
  • Radiation Applications Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran.

Zitieren

APA

Shafiei, S., & Yousefnia, H. (2026). Evaluation of cumulative absorbed dose in tumors of various sizes regarding 227Th-based targeted alpha therapy: an in-depth analysis. Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-025-02100-0

Vancouver

Shafiei S, Yousefnia H. Evaluation of cumulative absorbed dose in tumors of various sizes regarding 227Th-based targeted alpha therapy: an in-depth analysis. Annals of Nuclear Medicine. 2026. doi:10.1007/s12149-025-02100-0

BibTeX
@article{Shafiei2026,
  author = {Shafiei, Sepideh and Yousefnia, Hassan},
  title = {Evaluation of cumulative absorbed dose in tumors of various sizes regarding 227Th-based targeted alpha therapy: an in-depth analysis},
  journal = {Annals of Nuclear Medicine},
  year = {2026},
  doi = {10.1007/s12149-025-02100-0}
}
Kostenlos starten →